This was probably related to a study published
in March, 2004, which found a decreased rate of breast cancer recurrence
in women who were switched to Aromasin after being on tamoxifen for 2-3 years, as compared to those treated with tamoxifen for 5 years.
3. . Women on Aromasin were more likely to have fractures, joint pain, osteoporosis, visual disturbances, and diarrhea, while women on tamoxifen were more likely to report vaginal bleeding, muscle cramps, and blood clots.
4.